7,934 Shares in Twist Bioscience Corporation $TWST Acquired by Private Advisory Group LLC

Private Advisory Group LLC bought a new stake in shares of Twist Bioscience Corporation (NASDAQ:TWST – Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 7,934 shares of the company’s stock, valued at approximately $1,533,000.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the business. E. Ohman J or Asset Management AB acquired a new position in Twist Bioscience in the second quarter worth approximately $853,000. Allspring Global Investments Holdings LLC bought a new position in shares of Twist Bioscience in the first quarter valued at $22,563,000. Bank of America Corp DE lifted its position in shares of Twist Bioscience by 46.3% during the 1st quarter. Bank of America Corp DE now owns 584,261 shares of the company’s stock valued at $27,764,000 after acquiring an additional 184,907 shares during the last quarter. William Blair Investment Management LLC acquired a new stake in shares of Twist Bioscience during the 2nd quarter valued at $223,722,000. Finally, The Manufacturers Life Insurance Company bought a new stake in shares of Twist Bioscience during the 2nd quarter worth $8,215,000.

Insider Activity at Twist Bioscience

In other news, CFO Adam Laponis sold 2,462 shares of Twist Bioscience stock in a transaction dated Friday, October 9th. The stock was sold at an average price of $156.30, for a total transaction of $384,810.60. Following the completion of the sale, the chief financial officer directly owned 98,114 shares in the company, valued at $15,335,218.20. The trade was a 2.45% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CAO Robert Werner sold 1,482 shares of the business’s stock in a transaction that occurred on Friday, October 2nd. The shares were sold at an average price of $188.88, for a total value of $279,920.16. Following the completion of the sale, the chief accounting officer directly owned 42,917 shares of the company’s stock, valued at approximately $8,106,162.96. The trade was a 3.34% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders sold 495,279 shares of company stock worth $80,489,387. 3.08% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on TWST. UBS Group initiated coverage on Twist Bioscience in a research report on Wednesday, September 9th. They set a “neutral” rating and a $144.00 target price on the stock. BWS Financial reiterated a “sell” rating and issued a $45.00 price target on shares of Twist Bioscience in a research report on Friday, September 18th. TD Cowen dropped their price target on Twist Bioscience from $190.00 to $137.00 and set a “buy” rating on the stock in a research note on Friday. Jefferies Financial Group set a $125.00 price objective on Twist Bioscience in a report on Thursday. Finally, Piper Sandler upped their price objective on shares of Twist Bioscience from $85.00 to $115.00 and gave the company an “overweight” rating in a research note on Wednesday, August 5th. Seven research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $141.00.

Read Our Latest Research Report on TWST

Twist Bioscience Price Performance

Shares of NASDAQ:TWST opened at $111.60 on Monday. The company has a current ratio of 2.67, a quick ratio of 2.38 and a debt-to-equity ratio of 0.03. Twist Bioscience Corporation has a 1 year low of $23.30 and a 1 year high of $219.71. The business has a fifty day simple moving average of $150.23 and a 200 day simple moving average of $93.07. The firm has a market cap of $7.00 billion, a price-to-earnings ratio of -53.40 and a beta of 2.25.

Twist Bioscience (NASDAQ:TWST – Get Free Report) last released its quarterly earnings data on Thursday, November 12th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.07. Twist Bioscience had a negative return on equity of 27.53% and a negative net margin of 28.34%. The firm had revenue of $126.64 million during the quarter, compared to analysts’ expectations of $123.55 million. The business’s revenue was up 26.7% on a year-over-year basis. As a group, sell-side analysts predict that Twist Bioscience Corporation will post -1.52 earnings per share for the current fiscal year.

Twist Bioscience Company Profile

(Free Report)

Twist Bioscience Corporation is a biotechnology company that uses a silicon-based platform to manufacture synthetic DNA. Its technology supports the production of many DNA sequences in parallel for research and commercial applications. The company provides synthetic genes, gene fragments and oligonucleotide pools, as well as tools for next-generation sequencing, including target-enrichment products. Through its biopharma business, Twist also offers antibody discovery and related services to support the development of therapeutics.

Featured Stories

Want to see what other hedge funds are holding TWST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Twist Bioscience Corporation (NASDAQ:TWST – Free Report).

Institutional Ownership by Quarter for Twist Bioscience (NASDAQ:TWST)

Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.